Emily A. King

AbbVie (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index941citations15works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Associations and Epidemiology(7), Bioinformatics and Genomic Networks(3), Ferroptosis and cancer prognosis(3), Genomics and Rare Diseases(3), Computational Drug Discovery Methods(2)

Publications15 total

Integration of GWAS and multi-omic QTLs identifies uncharacterized COVID-19 gene-biotype and phenotype associations
2024Open Access
Stopped clinical trials give evidence for the value of genetics
Nature Genetics·2024
Machine learning reveals genetic modifiers of the immune microenvironment of cancer
iScience·2023· 2 citedOpen Access
Machine Learning Reveals Genetic Modifiers of the Immune Microenvironment of Cancer
2022Open Access
The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases
BMC Medical Genomics·2022· 76 citedOpen Access
Additional file 3 of The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases
Figshare·2022Open Access
Pathway specific polygenic risk scores identify pathways and patient clusters associated with inflammatory bowel disease risk, severity and treatment response
2021· 3 citedOpen Access
Estimating colocalization probability from limited summary statistics
BMC Bioinformatics·2021· 13 citedOpen Access
Additional file 2 of Estimating colocalization probability from limited summary statistics
Figshare·2021Open Access
Estimating colocalization probability from limited summary statistics
2020· 1 citedOpen Access
Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
PLoS Genetics·2019· 660 citedOpen Access
Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
2019· 76 citedOpen Access
An omnibus test for differential distribution analysis of microbiome sequencing data
Bioinformatics·2017· 109 citedOpen Access
Bayesian inference of virus evolutionary models from next-generation sequencing data
2017Open Access
SOMAscanTM v3.0: A Sensitive and Reproducible, Multiplex Proteomic Platform that Measures over 1100 Analytes in Complex Matrices
PubMed Central·2014· 1 citedOpen Access

Frequent Co-authors

J. Wade Davis(8), Jacob F. Degner(7), Sabrina Wollenhaupt(4), Jonas Reeb(4), Fengjiao Dunbar(3), Bridget Riley‐Gillis(3), Ammar J. Alsheikh(2), Sujana Ghosh(2), Lindsay R. Stolzenburg(2), Saleh Tamim(2), Jozef Lazar(2), Howard J. Jacob(2), Shirng‐Wern Tsaih(2), Amy R. Peck(2), Kelsey K. Wackman(2), Angela Lemke(2), Hallgeir Rui(2), Zoltán Dezső(2), Michael J. Flister(2), Jun Chen(1)